13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04943289 (ClinicalTrials.gov) | November 15, 2021 | 21/6/2021 | Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis | Phase IA Trial of Intrathecal Administration of Human Umbilical Cord Blood-Derived Cell Therapy (DUOC-01) in Adults With Primary Progressive Multiple Sclerosis (PPMS) | Primary Progressive Multiple Sclerosis | Biological: DUOC-01 | Joanne Kurtzberg, MD | NULL | Not yet recruiting | 18 Years | 65 Years | All | 20 | Phase 1 | United States |